Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
In this report we describe a patient suffering from chronic myeloid leukemia (CML), who was treated for 4.5 years with imatinib and developed pneumonia caused by two Candida species, i.e., C. krusei and C. glabrata. The patient was in complete hematologic remission and molecular analyses did not display the presence of TLR2-R752Q, TLR4-D299G and TLR4-T399I polymorphisms that may predispose individuals to fungal infections. This case report indicates that in some patients, as previously observed, the long-term administration of targeted therapy might affect immunity and predispose patients to opportunistic and life-threatening fungal infections.
Speletas
Matthaios
M
Department of Immunology and Histocompatibility, University of Thessaly Medical School, Larissa, Greece. speletas@otenet.gr
Vyzantiadis
Timoleon-Achilleas
TA
Kalala
Fani
F
Plastiras
Dimitrios
D
Kokoviadou
Kyriaki
K
Antoniadis
Antonios
A
Korantzis
Ioannis
I
D000368:Aged; D001549:Benzamides; D002175:Candida / Q000302:isolation & purification*; D002177:Candidiasis / Q000235:genetics / Q000382:microbiology*; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D009894:Opportunistic Infections / Q000235:genetics / Q000382:microbiology; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011014:Pneumonia / Q000235:genetics / Q000382:microbiology*; D011110:Polymorphism, Genetic; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D011859:Radiography; D051195:Toll-Like Receptor 2 / Q000235:genetics; D051197:Toll-Like Receptor 4 / Q000235:genetics
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D000068877:Imatinib Mesylate